SpyGlass Pharma Inc（SGP）股票分析

$32.240

-0.268 (-0.83%)收盤時

Loading chart…

最高: 32.925
開盤: 32.210
成交量加權均價: 32.31
成交量: 94.15K
市值: —
最低: 31.750
成交金額: 3.04M
企業價值/稅息折舊攤銷前利潤（TTM）: 0.00

SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.

spyglasspharma.com

AI 分析 of SpyGlass Pharma Inc (SGP)

買進

SpyGlass Pharma, Inc. (SGP) is a good buy right now due to its recent price performance, with a current price of $28.48 and a year-to-date change of +78.00%. The RSI is at 78.57, indicating strong momentum, while the forward P/E ratio is currently at 0, suggesting potential for future earnings growth. However, the main risk is the significant net loss of $19.9 million reported in Q2 2026, which reflects ongoing expenses that could impact short-term profitability.